Older age, brainstem syndrome, and polyfocal-specific magnetic resonance imaging presentation at onset are predictive of relapse risk in children with demyelinating diseases of the central nervous system.
Further understanding of the recently recognized symptomatic, measurable prodrome phase in multiple sclerosis will increase clinicians’ ability to diagnose and manage the disease earlier.
The use of immunosuppressive therapy (IST) prior to pregnancy in women with neuromyelitis optica spectrum disorder (NMOSD) is not associated with negative long-term outcomes.
The results of the identically designed ASCLEPIOS I and II phase 3 trials evaluating the effect of ofatumumab versus teriflunomide in participants with relapsing multiple sclerosis were presented at ECTRIMS 2019.
A high percentage of neurologists report diagnosing secondary progressive multiple sclerosis over a shorter period than that suggested by clinical guidance, and a greater number of neurologists who focus on multiple sclerosis diagnose and treat patients with SPMS than general neurologists.
Researchers find that a refinement of patient-reported outcome measures is needed to understand the drivers of underlying fatigue in patients with multiple sclerosis.
Janssen announced results from the phase 3 OPTIMUM study comparing treatment with ponesimod vs teriflunomide in patients with relapsing multiple sclerosis.
The risk for development of obstructive sleep apnea (OSA) and the severity of disease in patients with multiple sclerosis (MS) may be affected by the location of the lesions.
Among women with active relapsing-remitting multiple sclerosis, continuation of natalizumab treatment until the end of the first trimester is associated with significantly reduced disease reactivation compared with stopping natalizumab at conception.
Limited data are available regarding the satisfaction of patients with MS with their first diagnostic consultation (FDC). The goal of the current retrospective study was to identify FDC factors that may influence patient satisfaction.
Multiple sclerosis seems to prevent individuals from realizing their full potential at home and work, with fatigue being overwhelmingly identified as the cause, according to preliminary findings presented at ECTRIMS 2019.